BR100 Decreased By (-0.04%)
BR30 Decreased By (-0.26%)
KSE100 Decreased By (-0.01%)
KSE30 Decreased By (-0.01%)
AGHA 6.71 Increased By ▲ 0.03 (0.45%)
BECO 4.39 Increased By ▲ 0.02 (0.46%)
BML 56.89 Decreased By ▼ -0.43 (-0.75%)
BOP 30.29 Decreased By ▼ -0.06 (-0.2%)
CNERGY 13.10 Decreased By ▼ -0.02 (-0.15%)
CSIL 5.33 Decreased By ▼ -0.08 (-1.48%)
FCCL 52.65 Decreased By ▼ -0.14 (-0.27%)
FFL 14.61 Decreased By ▼ -0.11 (-0.75%)
FNEL 1.13 Increased By ▲ 0.01 (0.89%)
KEL 6.13 Increased By ▲ 0.04 (0.66%)
KOSM 6.15 Increased By ▲ 0.42 (7.33%)
LOTCHEM 26.52 Increased By ▲ 0.06 (0.23%)
MLCF 93.15 Decreased By ▼ -0.01 (-0.01%)
NBP 164.90 Increased By ▲ 0.24 (0.15%)
NCPL 55.67 Increased By ▲ 0.01 (0.02%)
NPL 60.80 Decreased By ▼ -0.36 (-0.59%)
OGDC 315.89 Decreased By ▼ -0.84 (-0.27%)
PACE 9.99 Increased By ▲ 0.12 (1.22%)
PAEL 35.59 Decreased By ▼ -0.04 (-0.11%)
PIBTL 14.84 Increased By ▲ 0.16 (1.09%)
PPL 224.89 Decreased By ▼ -2.02 (-0.89%)
PRL 92.85 Decreased By ▼ -0.17 (-0.18%)
PTC 60.25 Decreased By ▼ -0.01 (-0.02%)
SSGC 23.79 Decreased By ▼ -0.02 (-0.08%)
TBL 8.78 Increased By ▲ 0.03 (0.34%)
TELE 7.79 Decreased By ▼ -0.01 (-0.13%)
TPL 22.35 No Change ▼ 0.00 (0%)
TPLP 12.82 Decreased By ▼ -0.15 (-1.16%)
TREET 22.16 No Change ▼ 0.00 (0%)
TRG 56.72 Increased By ▲ 0.16 (0.28%)
Pakistan Print edition: 2025-02-20

Clinical Trials Summit concludes

Published Updated

KARACHI: The Clinical Trials Summit of Pakistan 2025 marked a significant milestone for the country’s healthcare landscape.

Hosted by the Clinical Trials Unit (CTU) at Aga Khan University (AKU), in collaboration with National University of Medical Sciences (NUMS), this two-day event brought together leading professionals, researchers, and healthcare providers to discuss the latest trends, challenges, and advancements in clinical trials.

Dr Saeed Hamid, Director of the Clinical Trials Unit at AKU, reflected on the impact of global clinical trials, stating: “One satisfying aspect of participating in global clinical trials is the opportunity for our patients to experience cutting-edge therapies for diseases, such as hepatitis Delta, which currently have no approved treatment available.”

Dr Bin Chen, CEO of HuaHui Health, commented on the summit’s success in fostering collaboration, stating that “The conference was an exceptional platform for collaboration, innovation, and knowledge-sharing.”

Notable sessions included discussions on the current landscape of clinical trials in Pakistan, with experts from a wide range of national and international organizations providing valuable perspectives on strengthening clinical trials through best practices. Additionally, a session on regulatory frameworks and global best practices was chaired by Dr Obaidullah, Director of the Drug Regulatory Authority of Pakistan (DRAP), and Mr. Abdullah Abro, Chair of the Clinical Studies Committee at DRAP, while in-depth discussions on advancing oncology clinical trials, emphasized the need for building consortia for better access to cancer treatments.

Dr Khalid Matin, Professor of Medicine at VCU Massey Comprehensive Cancer Centre in the USA, emphasized the importance of inclusion in global cancer research, stating: “We need to work together to ensure the inclusion of patient populations globally in cancer research. Access to clinical trials is an important part of the standard of care in oncology.”

Dr Shalaan Beg, Adjunct Associate Professor at the University of Texas, highlighted the vital role of oncology clinical trials, saying: “The Clinical Trials Summit was an essential step in aligning government regulators, the pharmaceutical industry, and local clinical trial infrastructure to bring more trials to Pakistan.”

Aga Khan University’s Clinical Trials Unit (CTU), established in 2011, continues to be a leader in advancing clinical research in Pakistan. As the country faces a higher-than-average disease burden, the CTU is committed to developing innovative solutions tailored to local healthcare needs.

Copyright Business Recorder, 2025

Comments

Comments are closed for this article.